HomeCompareMXYKX vs ABBV

MXYKX vs ABBV: Dividend Comparison 2026

MXYKX yields 13.79% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $54.2K in total portfolio value· pulled ahead in Year 6
10 years
MXYKX
MXYKX
● Live price
13.79%
Share price
$4.65
Annual div
$0.64
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.5K
Annual income
$3,244.91
Full MXYKX calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — MXYKX vs ABBV

📍 ABBV pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMXYKXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MXYKX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MXYKX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MXYKX
Annual income on $10K today (after 15% tax)
$1,172.45/yr
After 10yr DRIP, annual income (after tax)
$2,758.17/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $18,767.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MXYKX + ABBV for your $10,000?

MXYKX: 50%ABBV: 50%
100% ABBV50/50100% MXYKX
Portfolio after 10yr
$76.6K
Annual income
$14,284.84/yr
Blended yield
18.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MXYKX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MXYKX buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMXYKXABBV
Forward yield13.79%3.09%
Annual dividend / share$0.64$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$49.5K$103.7K
Annual income after 10y$3,244.91$25,324.79
Total dividends collected$22.8K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MXYKX vs ABBV ($10,000, DRIP)

YearMXYKX PortfolioMXYKX Income/yrABBV PortfolioABBV Income/yrGap
1$12,079$1,379.35$11,555$434.96+$524.00MXYKX
2$14,482$1,557.17$13,485$635.47+$997.00MXYKX
3$17,241$1,744.77$15,933$937.67+$1.3KMXYKX
4$20,389$1,941.23$19,118$1,400.80+$1.3KMXYKX
5$23,961$2,145.51$23,384$2,125.24+$577.00MXYKX
6← crossover$27,995$2,356.51$29,290$3,286.81$1.3KABBV
7$32,528$2,573.10$37,776$5,205.38$5.2KABBV
8$37,599$2,794.13$50,495$8,488.44$12.9KABBV
9$43,249$3,018.44$70,497$14,346.44$27.2KABBV
10$49,522$3,244.91$103,718$25,324.79$54.2KABBV

MXYKX vs ABBV: Complete Analysis 2026

MXYKXStock

The fund will, under normal circumstances, invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities of mid-capitalization (“mid cap”) companies. For purposes of the 80% policy, the manager considers mid cap companies to be those whose market capitalization falls within the range of the Russell MidCap ® Growth Index at the time of initial purchase.

Full MXYKX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MXYKX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MXYKX vs SCHDMXYKX vs JEPIMXYKX vs OMXYKX vs KOMXYKX vs MAINMXYKX vs JNJMXYKX vs MRKMXYKX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.